EGFR and non-small cell lung carcinoma: EGFR mutations with exon 19 deletions and L858R point mutation in exon 21 occur most frequently in NSCLC, and have a high response rate of approximately 70% to EGFR tyrosine kinase inhibitor (TKI) therapy [4, 6, 8, 9].